Analysts Set Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Target Price at $11.67

Shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV) have earned a consensus rating of “Moderate Buy” from the five ratings firms that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $11.6667.

Separately, Weiss Ratings lowered shares of Acrivon Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday.

Institutional Trading of Acrivon Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Jane Street Group LLC increased its position in Acrivon Therapeutics by 18.3% in the fourth quarter. Jane Street Group LLC now owns 342,071 shares of the company’s stock worth $824,000 after buying an additional 52,823 shares during the period. Goldman Sachs Group Inc. boosted its holdings in shares of Acrivon Therapeutics by 504.9% during the fourth quarter. Goldman Sachs Group Inc. now owns 119,422 shares of the company’s stock valued at $288,000 after acquiring an additional 99,680 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Acrivon Therapeutics by 3.2% during the fourth quarter. Geode Capital Management LLC now owns 198,223 shares of the company’s stock valued at $478,000 after acquiring an additional 6,190 shares during the period. Algert Global LLC bought a new position in shares of Acrivon Therapeutics during the third quarter worth about $81,000. Finally, Two Sigma Investments LP grew its position in shares of Acrivon Therapeutics by 76.2% during the third quarter. Two Sigma Investments LP now owns 319,205 shares of the company’s stock worth $578,000 after acquiring an additional 138,033 shares during the last quarter. 71.62% of the stock is currently owned by institutional investors and hedge funds.

Acrivon Therapeutics Stock Performance

Shares of NASDAQ:ACRV opened at $1.72 on Monday. The firm has a market cap of $73.62 million, a PE ratio of -0.86 and a beta of 1.82. The company has a fifty day simple moving average of $1.70 and a 200 day simple moving average of $1.78. Acrivon Therapeutics has a 12-month low of $1.20 and a 12-month high of $3.56.

Acrivon Therapeutics (NASDAQ:ACRV) last issued its earnings results on Wednesday, May 13th. The company reported ($0.49) EPS for the quarter, hitting the consensus estimate of ($0.49). As a group, equities research analysts forecast that Acrivon Therapeutics will post -1.92 EPS for the current fiscal year.

About Acrivon Therapeutics

Acrivon Therapeutics (NASDAQ:ACRV) is a clinical-stage biotechnology company focused on the discovery and development of stapled peptide therapeutics for the treatment of RAS-driven cancers. Its proprietary platform is designed to enhance the stability, cell permeability and target specificity of peptide molecules, enabling the disruption of protein–protein interactions that are traditionally challenging to inhibit with small-molecule drugs or biologics.

The company’s lead development candidate is a hydrocarbon-stapled peptide selectively targeting the KRAS G12C mutation, currently in early clinical trials.